{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:58:07Z","timestamp":1779296287696,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunoglobulin dosing is individualised in chronic inflammatory demyelinating polyneuropathy (CIDP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively compared differences in presentation\/outcomes\/side effects in subjects on very high dose immunoglobulin defined as \u2265\u20092\u2009g\/kg every 3\u2009weeks (\u2018Group A\u2019) and subjects on \u2264\u20091\u2009g\/kg every 3\u2009weeks (\u2018Group B\u2019), from 2 UK centres.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One\u2010hundred and eight subjects with CIDP received immunoglobulins. Group A consisted of 12 subjects (11.1%). Mean dose was 2.63\u2009g\/kg every 3\u2009weeks (SD: 0.71). Six subjects (50%) had typical CIDP, 3 (25%) had motor CIDP, and 3 (25%) had multifocal CIDP. Group B consisted of 40 subjects (37%) on a mean dose of 0.47\u2009g\/kg every 3\u2009weeks (SD: 0.16). Compared to subjects from Group B, subjects from Group A had greater pre\u2010treatment disability (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029), more common associated autoimmune disease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.034), worse post\u2010treatment outcome (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005) and a longer time to maximal improvement (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041). No differences were found between the two groups for age\/gender\/weight\/acuteness of presentation\/side\u2010effects. Occurrence of any side\u2010effect (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005), and of thromboembolic complication (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022), were associated with presence of another autoimmune disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Very high dose immunoglobulin may be partially effective in a minority of subjects with CIDP. Subjects treated with very high dose immunoglobulin may have greater pre\u2010treatment disability, be more likely to have another autoimmune disease, have worse post\u2010treatment outcomes, and take longer to reach maximal improvement, than subjects on lower doses. Concurrent autoimmune disease may increase immunoglobulin\u2010induced thromboembolic risk. Earlier consideration of alternative therapies may be more appropriate than immunoglobulin dose escalation in subjects with suboptimal immunoglobulin response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.70429","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:35:14Z","timestamp":1763537714000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Very High Dose Immunoglobulin Treatment for Chronic Inflammatory Demyelinating Polyneuropathy: A Multicentre UK Study"],"prefix":"10.1111","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7170-8343","authenticated-orcid":false,"given":"Yusuf A.","family":"Rajabally","sequence":"first","affiliation":[{"name":"Aston Medical School Aston University  Birmingham UK"},{"name":"Inflammatory Neuropathy Service, Department of Neurology University Hospitals Birmingham  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joumana","family":"Freiha","sequence":"additional","affiliation":[{"name":"Wessex Neurological Centre University Hospital Southampton  Southampton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0930-5997","authenticated-orcid":false,"given":"Young Gi","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Neurology Seoul National University College of Medicine  Seoul Republic of Korea"},{"name":"Department of Neurology Severance Hospital, Yonsei University College of Medicine  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8245-0942","authenticated-orcid":false,"given":"Chinar","family":"Osman","sequence":"additional","affiliation":[{"name":"Wessex Neurological Centre University Hospital Southampton  Southampton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"e_1_2_8_2_1","article-title":"Treatments for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): An Overview of Systematic Reviews","volume":"1","author":"Oaklander A. L.","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)92400-4"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70329-0"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12158"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9157-4"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27046"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2006.00105.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-6938-7"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304670"},{"key":"e_1_2_8_11_1","volume-title":"Commissioning Criteria Policy for the Use of Therapeutic Immunoglobulin (Ig) England","author":"NHS England Immunoglobulin Expert Working Group","year":"2024"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab422"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574886313666181017121139"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16399"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318208824b"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26747"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/00207454.2020.1815733"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/00207454.2016.1269328"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332844"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae400"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152707"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47040291"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160185"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.05.035"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008742"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.2366"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102016"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T07:01:27Z","timestamp":1764313287000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.70429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/ene.70429"],"URL":"https:\/\/doi.org\/10.1111\/ene.70429","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2025-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70429"}}